Rznomics

Rznomics is a biotech company developing RNA-editing gene therapies using its proprietary trans-splicing ribozyme-based RNA-replacing enzyme platform.

Its core pipeline candidate is RZ-001, an anticancer agent targeting hepatocellular carcinoma (HCC) and glioblastoma (GBM), which works by targeting and cleaving the hTERT gene and inserting a gene that triggers sensitivity to an antiviral agent.

RZ-001 is being tested in Phase 1b/2a trials in Korea and the US in combination with the first-line HCC standard-of-care regimen Tecentriq (atezolizumab) and Avastin (bevacizumab), with atezolizumab supplied by Roche and the bevacizumab-class drug supplied by a domestic biopharmaceutical company.

The GBM indication has received both Orphan Drug Designation and Fast Track status from the US FDA, along with approval for an Expanded Access Program (EAP).

The platform's expansion pipeline includes an Alzheimer's disease candidate, RZ-003, and a retinal disease candidate, RZ-004, most of which are planned for co-research or licensing with partners at the preclinical stage.

In May 2025, the company signed a strategic global license agreement with Eli Lilly for joint development of a hereditary hearing loss treatment, under which Rznomics handles early-stage R&D while Lilly manages subsequent development and commercialization.

The company has no commercialized product revenue to date, with a substantial portion of its revenue derived from partnership-related items such as R&D funding received from Lilly. Rznomics is also expanding its research scope into in vivo CAR-T therapy using its circular RNA platform.

Consolidated 2025 revenue reached KRW 7.92 billion, the first meaningful revenue figure compared with zero in both 2024 and 2022, yet the annual operating loss remained at KRW 14.6 billion, continuing a persistent loss structure.

Net loss attributable to owners expanded sharply to KRW 103.8 billion in 2025 from KRW 18.9 billion in 2024, KRW 13.6 billion in 2023, and KRW 31.5 billion in 2022, with the quarterly breakdown showing this was concentrated in the second quarter of 2025.

That quarter saw revenue of KRW 7.09 billion and a rare operating profit of KRW 3.06 billion, yet the net loss still reached KRW 85.07 billion, suggesting non-operating items heavily distorted the bottom line.

Subsequent quarters saw revenue shrink again, with operating losses persisting each quarter: zero revenue and an KRW 8.08 billion operating loss in Q3 2025, KRW 0.83 billion revenue and KRW 5.44 billion operating loss in Q4 2025, KRW 0.37 billion revenue and KRW 8.06 billion operating loss in Q1 2026, and KRW 0.81 billion revenue and KRW 6.85 billion operating loss in Q2 2026.

The combined net loss attributable to owners over the most recent four quarters (Q3 2025 through Q2 2026) was KRW 27.6 billion, indicating the pace of cash consumption has remained elevated even after listing.

Operating cash flow was negative every year from 2022 through 2025, ranging between roughly KRW -10.8 billion and KRW -14.4 billion, showing that actual cash outflow has continued steadily regardless of accounting revenue recognition.

Consolidated equity was negative throughout 2022-2024 (KRW -62.6 billion, -74.7 billion, and -93.2 billion respectively) before turning positive to KRW 58.9 billion in 2025, likely reflecting the reclassification of redeemable convertible preferred shares from liabilities to equity around the listing.

The debt ratio also shifted from -130.2% in 2024 to 6.7% in 2025, though the negative figures in prior years reflected a capital-impairment state, limiting the meaningfulness of a direct comparison.

The RNA-based gene therapy and editing therapy industry has recently drawn intense interest from global big pharma, and Korean RNA-related stocks broadly rallied together after Moderna announced Phase 3 success for its personalized mRNA cancer vaccine, reflecting heightened investor attention in the space.

The hereditary hearing loss treatment field has begun to open commercially after a Regeneron therapy received the first-ever FDA approval in the category, an event relevant to the commercial context of the program Rznomics is co-developing with Lilly.

Korea's RNA and gene therapy sector includes several companies such as ST Pharm and Olix, and Rznomics is attempting to differentiate itself by having reached the stage of securing clinical proof-of-concept data for its own platform.

In the liver cancer treatment market, an existing first-line standard-of-care combination of an immuno-oncology agent and an anti-angiogenic drug is already well established, meaning any new combination option must demonstrate a clear improvement in safety or efficacy to penetrate the competitive landscape.

In terms of business model, biotechs in this space typically pursue licensing of platforms and pipelines to large pharmaceutical companies rather than self-commercialization, and Rznomics has stated it has additional partners under confidentiality agreements beyond Lilly.

The broader KOSDAQ biotech sector tends to show significant share price volatility around clinical data disclosure timings, with conference presentations and regulatory designations serving as key events driving investor attention.

In April 2026 Rznomics gave an oral presentation of interim dose-escalation results from the RZ-001 Phase 1b liver cancer trial at the American Association for Cancer Research (AACR) meeting, prompting sell-side commentary suggesting the data could accelerate the pace of development and licensing discussions.

This was followed in May by RMAT designation from the US FDA for RZ-001's HCC indication, opening the possibility of accelerated development and approval strategy through closer FDA engagement going forward.

The GBM indication has already secured Orphan Drug and Fast Track designations along with EAP approval, making the timing of further clinical data disclosure the next point to watch.

At the time of listing, the company disclosed that beyond Lilly, two additional global pharmaceutical companies had agreed to enter confidentiality agreements and discussions once clinical proof-of-concept data was secured, making it a key watch point whether the recent clinical data will catalyze further licensing talks.

The company has also stated that its Alzheimer's candidate RZ-003 is targeted for licensing at the preclinical stage, with near-term progress expected within one to two years.

Expansion into in vivo CAR-T therapy using the circular RNA platform, and plans to extend delivery-technology partnerships overseas, are also in progress.

The Lilly agreement structures R&D funding around annual milestone achievements, and the continued receipt of funding in 2025 and Q1 2026 can serve as an indicator of the partnership's ongoing continuity.